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The global division over genetically modified (GM) foods has, by now, assumed a familiar 
dimension. In the United States and Canada, farmers routinely grow GM varieties of 
crops and consumers readily (if unknowingly) eat foods containing ingredients derived 
from GM crops. The US media have paid relatively little attention to GM foods, and 
while one cannot say that the public has accepted GM foods, it is clear that the majority 
of US consumers do not view GM foods with active concern. Indeed, the most salient 
finding of numerous polls is that US consumers remain largely uninformed about GM 
foods and their presence in the food supply (Hallman, 005; PIFB, 005).
The situation is far different in other parts of the world—parts of the world that also 
happen to be major markets for US farm exports. European consumers in particular are 
hostile to GM crops and food. Even when approved as safe by European Commission 
regulators, few GM foods are available for sale in the EU because retailers and manufac-
turers fear hostile consumer reaction to foods labeled as containing genetically modified 
organisms (GMOs) (USDA, 005). As a consequence, the global market for commodi-
ties like corn has been divided into GM and non-GM zones, complicating trade. In part 
because of these trade disputes and market uncertainties, the future for new GM-food 
crops is clouded.
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The question is whether plant biotechnology1 can be harnessed to provide benefits out-
side of the area of food and feed. Can the kind of global deadlock that has emerged from 
the introduction of GM crops and food be avoided? Is the opposition to the use of plant 
biotechnology limited to its use in food, or can the potential health and environmental 
benefits of the next-generation of plant biotechnology change the contours of the global 
debate? What are some of the obstacles that await the commercialization of health and 
environmental applications of plant biotechnology? 
The temptation to generalize too much should be resisted. Experience and common 
sense suggest that every application is likely to have its own opportunities and challenges, 
and across-the-board predictions are likely to be misleading. Some of the issues specific to 
different types of applications are explored later in this paper. Nevertheless, any new GM 
plant is likely to have to face four critical hurdles that will require both time and money to 
overcome on the road to commercialization. Some of these hurdles are no different from 
those faced by any novel product, while others are unique to products developed through 
biotechnology. First, of course, is the development of the product itself—proving technical 
and economic feasibility. Second, products of plant biotechnology need stewardship and 
management beyond that required for plants developed through conventional breeding, 
both as a requirement of regulators as well as the necessity of sound business practice. 
Third, plant biotechnology products need to pass through a regulatory review and ap-
proval process that involve both direct and indirect costs. Finally, as with any product, a 
plant biotechnology product must meet the ultimate marketplace test: are there buyers 
willing to buy it at a price that delivers a profit to the developer?
the Market Potential of Health and Environmental 
Biotech Applications
A number of products are being developed through plant biotechnology that could 
have significant health or environmental benefits beyond food or feed. Understanding 
what the potential market may be for these applications is an important starting point 
in understanding the hurdles that they face on the road to commercialization. Other 
contributors to this volume will develop these points in much greater detail, so only a 
summary is offered here.
Plant-Made	Pharmaceuticals
The potential economic and safety benefits of producing therapeutic proteins from plants 
have been explored in a number of venues (PIFB, 00; BIO, 005a). The market for 
antibodies is projected to be $ billion by the year 00 (Novis, 005), but current 
production practices for antibodies cannot keep pace with demand and there appears 
to be a significant supply shortfall. In particular, the costs associated with scaling up 
traditional bioreactors using animal or microbial cells create a significant bottleneck in 
1For the purpose of this paper, the term “biotechnology” is used in the popular (rather than scientific) sense to 
refer to recombinant DNA techniques. Similarly, the terms “genetically modified” and “transgenic” are used 
interchangeably and refer to plants modified through recombinant DNA technology to introduce novel or 
enhanced traits.
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the development of therapeutic proteins. One of the potential advantages of plant-made 
pharmaceuticals (PMPs) would be the ability to scale up relatively quickly and at relatively 
low cost. In addition, there may be fewer safety concerns about proteins derived from 
plants rather than from animal cells. 
Unlike food-biotech applications, PMPs potentially distribute benefits along the value 
chain. For farmers, growing a high-value crop from low-cost commodity species could 
offer a way to enhance farm income. For consumers, the potential lower cost of thera-
peutic proteins would be of considerable benefit. For that reason, it is not surprising that 
the use of biotechnology to create lower-cost pharmaceuticals remains one of the reasons 
most strongly supported by the US public (PIFB, 005). The potential application of the 
technology to develop vaccines that may be of particular benefit to developing countries 
is also the subject of considerable research and development effort in the non-profit arena 
(Mason et	al., 00).
Forestry	Applications
The application of biotechnology to forestry would also appear to have significant mar-
ket advantages. Increasing demand for wood and wood products from a growing world 
population poses a challenge for forestry management and forest-product companies, 
which are increasingly under pressure to reduce logging in natural forests and to adopt 
environmentally sustainable practices (Hardaker, 997; Brooks, 00; PIFB, 00). 
While these pressures have led to the development of forest plantations carefully managed 
to enhance growth, commercial forestry has not yet captured the benefits of improved 
genetics that have accounted for significant productivity gains in crop agriculture. The 
use of biotechnology may provide an opportunity for forestry to make genetic improve-
ments more quickly that could help increase yields by reducing disease, improving pest 
resistance, and promoting faster growth. In addition, the use of biotechnology to control 
certain traits more directly could lead to the introduction of trees better suited for pro-
cessing in specific applications, such as pulp and paper (PIFB, 00; ArborGen, 00; 
El-Lakany, 00).
The spread of disease among major species of trees in the United States, including 
elms, chestnuts, oaks and the eastern dogwood, has also created an urgent need to de-
velop disease-resistant varieties. While research using conventional breeding techniques 
continues, biotechnology may offer a way to introduce desirable disease-resistance traits 
more quickly (Osusky, 000; PIFB, 00; ArborGen, 00;).
Phytoremediation
The clean up of environmentally contaminated sites remains a huge challenge in this 
The	market	for	antibodies	is	projected	to	be	$26	billion	by	the	
year	2010,	but	current	production	practices	for	antibodies	cannot	
keep	pace	with	demand.
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country. The Environmental Protection Agency (EPA) estimates that tens of thousands 
of contaminated sites still need clean up in the United States (EPA, 00). In most cases, 
the technology of choice is simply to dig up contaminated soil and cart it to some other 
place. technologies for treatment in	 situ remain costly and controversial. Phytoreme-
diation offers a number of potential benefits, including lower costs, better performance 
and greater public acceptability (EPA, 005). According to EPA (005), field trials of 
phytoremediation techniques have reached a promising stage, and estimated costs of 
various phytoremediation techniques vary from 0% to 50% of physical, chemical, or 
thermal clean-up techniques. At the same time, phytoremediation is likely to be useful 
for only a small subset of affected sites where the contaminants lie within the root zone 
(EPA, 005). Estimates made in the late 990s suggested that the domestic market for 
phytoremediation ranged from $3 million to $30 million, with projections ranging as 
high as $370 million by 005 (Kidney, 997; Glass, 998). Given this extraordinarily 
wide range of estimates, it is clear that there is still significant uncertainty about the 
potential market for the application of phytoremediation, and that much will depend 
on how well phytoremediation actually performs in-site clean ups. The goal of research 
is to use biotechnology to develop plants that are more efficient, further reducing costs 
and potentially decreasing the time it takes to decontaminate a site.
There	is	still	significant	uncertainty	about	the	potential	market	
for	the	application	of	phytoremediation.
threshold Question: Who Bears the Cost of 
Product Development?
Clearly, there appear to be significant market opportunities for applications in these three 
areas. However, the threshold question faced by any developer is easy enough to state: who 
is going to pay the cost of taking the product through all of the critical stages of proof of 
concept, development, testing, regulatory approvals and marketing? For the private sector, 
products can be self-financed if the developer is a large, well capitalized company with 
r&D budgets, but small businesses and start-ups will need to look to venture capital and 
partnerships to sustain them through the development and approval processes. 
The willingness of the private sector to invest in product development will depend 
largely on the anticipated return on investment, which includes not only consideration of 
potential revenues downstream, but also the costs associated with the process of bringing 
a product to market. Products that are likely to be commercialized through traditional 
private-sector incentives are those for which there is a well defined and profitable mar-
ket. In addition, the private sector will tend to invest in products only where there is 
strong intellectual-property protection to prevent potential “free rider” and competition 
problems. On the cost side of the equation, some of the uncertainties unique to plant-
biotechnology products make predicting development costs more difficult and raise the 
risk for investors. 
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As the history of the development of plant biotechnology demonstrates, many poten-
tial applications are unlikely to meet the conditions for private-sector development and 
investment. In some instances, products may lack a viable market capable of returning 
sufficient revenues—such as in the case of niche food crops or the development of plants 
modified to provide vaccines for endemic diseases in the developing world. In other 
instances, steep development or regulatory costs or uncertainty about market acceptance 
could deter private-sector development. If products with potential “public” value are 
going to be developed, they will have to come from the non-profit sectors: government, 
university, and other non-profit research institutions. 
But the non-profit developer faces the same question: where does the money come 
from to pay the cost of taking a plant-biotechnology product through all the required 
steps? Since non-profit developers tend to focus on the “public goods” that are unlikely 
to return a profit to a private investor, they must rely on sources of funding from govern-
ments, foundations and other donors. The funding plight of non-profit plant-breeding 
research in the United States and throughout the world has been well documented (Frey, 
99; Heisey et	al., 00). While most plant breeding used to be in the public sector, 
private-sector research now dominates as a result of declining public funding and new 
forms of intellectual-property rights and modern biotechnology that spurred increased 
private investment (Alston, 00).
The	funding	support	for	plant-biotechnology	products	that	are	
truly	“public	goods”	remains	a	serious	problem.	
Non-profit institutions face additional challenges when it comes to the use of agricul-
tural biotechnology and plant-breeding programs. Such institutions traditionally have 
little experience with the stewardship and regulatory issues associated with the manage-
ment and development of bioengineered crops. In an environment characterized by scarce 
resources, the increased costs and uncertainties faced by products of plant biotechnology 
also operate as a significant constraint. In some instances, particularly where a product has 
some potential for commercialization, non-profit organizations may enter into partner-
ships or licensing agreements with private-sector entities that have more experience in 
commercialization as well as the management capabilities to deal with stewardship and 
regulatory issues. However, the interest of the private sector in such partnerships will still 
be limited by the potential profitability of the product. As a result, the funding support for 
plant-biotechnology products that are truly “public goods” remains a serious problem. 
Speed Bumps in the road to Market
The threshold question, stated above, is simple: who pays? The next question, of course, is: 
how much? Surmounting the hurdles of development, management, regulatory approval 
and commercialization all require investments of time, resources, and money. Having a 
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clear understanding of those costs is critical to all developers, but is of particular interest to 
private-sector developers and investors who are making business decisions about whether 
or not to invest in the technology. Below, the potential costs—and uncertainties—associ-
ated with each stage, with reference to health and environmental plant biotechnology 
applications, are considered in more detail. 
Technical	and	Economic	Feasibility
The initial hurdle, of course, is technical feasibility—that is, simply getting the technology 
to work. It is one thing to get a protein expressed in a plant in a laboratory; it’s another 
thing altogether to get the trait expressed in a plant in the real world. Proponents of bio-
technology have been talking about the remarkable promise of this technology for more 
than 0 years, but the only two commercially significant traits on the market today are 
herbicide tolerance and insect resistance. Part of the reason for the relatively few traits 
is that getting plants to do some of the things that developers long ago envisioned has 
proven to be more difficult than originally expected. 
For example, Ingo Potrykus’s development saga of “golden rice” continues today, years 
after the original concepts and early products were tested. researchers are now following 
up on the recent development of SGr, a golden rice variety developed by Syngenta that 
may produce ten times as much beta-carotene as the original SGr variety (Derham, 
005). Drought tolerance, a trait long pursued by plant-biotech developers in the private 
and non-profit sectors, appears at last to be close to moving toward the regulatory ap-
proval phase (Melcer, 00). Even when gene sequences are successfully identified, it takes 
time to integrate that trait successfully into a variety with desirable agronomic or output 
traits. The science of plant genomics is moving ahead quite rapidly, but the complexity 
of gene modification to achieve commercially acceptable output or input traits is still a 
time-consuming and somewhat uncertain process.
One issue related to technical feasibility is access to intellectual property (IP). The 
impact of the introduction of strong IP-protection schemes in the plant-breeding and 
plant-biotech world remains a hotly debated issue. However, it seems fairly clear that, 
at a minimum, the development of strong IP-protection schemes raises the transaction 
costs (in time and money) for non-profit developers by requiring due-diligence searches 
to avoid infringement and to negotiate licensing arrangements when needed. On the 
other hand, strong IP protection is a precondition to investment by the private sector 
(Alston, 00; BIO, 005b).
Proving technical feasibility clearly remains a challenge for a number of specific non-
food health and environmental plant-biotech applications. For pharmaceutical crops, for 
example, it remains to be seen whether plants can be modified and grown in a manner 
that allows consistent expression of the protein, and whether the protein will prove to be 
clinically equivalent and equally safe and effective as those grown in animal-cell cultures. 
Merispase®, a PMP designed to treat a condition that affects patients with cystic fibrosis, 
has been through some phase-II clinical trials intended to answer these types of questions 
(Meristem, 005). Whether the predicted cost efficiencies will be realized is another key 
issue associated with proof of concept for PMPs.
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Biotechnology applications to forestry are complicated by limited scientific knowledge 
of tree genomics as well as the inherent complexity of engineering an organism intended 
to grow for years before harvesting (PIFB, 00). For example, it is possible that genetic 
changes could result in undesirable effects that would not be observed until after several 
years growth. Ensuring consistent expression of traits over the lifetime of a tree is also 
important for traits like insect and disease resistance (PIFB, 00).
In the area of phytoremediation, there are promising laboratory and field-trial develop-
ments using genetic modifications to enhance plants’ abilities to take up environmental 
contaminants such as metals (Bañuelos et	al., 005). The question, of course, is how well 
such plants will work in the real world of contaminated sites; to date, field-trial data have 
been limited to simulated contaminated sites. For reasons discussed later in this paper, 
more compelling data of the efficacy and efficiency of this technology are likely to be 
needed before it will be applied in real-world environmental clean ups.
Product	Management	and	Stewardship
The second hurdle is the cost of management and stewardship associated particularly with 
the development of bioengineered plants. Because of the environmental, food-safety, and 
marketing issues associated with bioengineered plants, they require special handling and 
management to ensure containment and, in some cases, tracking and identity preserva-
tion. Management and stewardship requirements start early in the development process, 
long before a plant may be ready to be commercialized; indeed, key product-development 
phases, including field trials, will be required to be under US Department of Agriculture 
(USDA) permit. 
Arguably, these stewardship and management costs could be considered a part of regula-
tory compliance costs, because in many cases these requirements are actually mandated by 
regulatory agencies—as with USDA transportation and field-trial permits or notifications. 
On the other hand, it could also be argued that bioengineered crops would be subject to 
special handling and management even in the absence of regulatory requirements given 
potential concerns about liability under the common law of torts (Kershen, 00) or to 
fulfill private contractual requirements. Particularly in the wake of the StarLink™ episode, 
seed companies, farmers, grain distributors and processors, and others in the food-produc-
tion chain have become more conscious of the need to adopt best management practices 
to ensure that customers are getting what has been represented, and to avoid potential 
liability for GM-plant products mixing with plants where GM components are undesir-
able for any number of reasons.
However, as a representative of ProdiGene (00) noted in a recent comment to 
USDA:
…no	matter	what	system	of	production	is	employed,	accidents,	natural	disasters,	
or	other	unforeseen	events	may	allow	the	loss	of	containment	despite	best	efforts....	
[D]espite	adherence	 to	 rigorous	 containment	protocols,	 low	 level	products	not	
intended	for	food	or	feed	have	the	potential	to	be	present	in	commercial	crops	
at	some	time.
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Given this potential, developers and investors seeking to reduce potential exposure to risk 
are likely to consider the availability of liability insurance in this area.
Part of the difficulty faced by developers and investors in this area is the lack of clarity 
and certainty about the standards to which they are being held accountable. At the present 
time, there are no legally binding standards or even guidelines to provide developers a 
“clear harbor” for adventitious presence. In the absence of legislation or regulation, liability 
will be determined through the rather ineffective process of litigation. to date, few cases 
have been litigated that shed any light on appropriate duties and responsibilities, leaving 
the field ripe for speculation by lawyers in law-review articles (Kershen, 00). 
Not even the regulatory agencies have taken on the task of defining tolerances or 
thresholds for materials from GM plants that have not completed the regulatory review 
process. Instead, USDA and EPA have imposed conditions on field trials that are, as a 
practical matter, intended to prevent any gene flow and thereby achieve a zero-tolerance 
level (PIFB, 00b). Not only are these conditions expensive to follow, their existence 
implies there may be a legal liability for even a de-minimus level of contamination. It is 
also unclear if these conditions will be successful 00% of the time.
This issue has already been a particular challenge for developers of PMPs. Farmers, food 
manufacturers and others have expressed concern about any mixing of PMPs with food or 
feed crops, even if such mixing is unlikely to raise any environmental or health concern 
(Nutraceuticals International, 003). Clearly, food manufacturers are concerned about 
the potential economic damage to their brands in the event of a publicized event where 
PMPs are found in their products. Growers are concerned that even the remote possibil-
ity of adventitious presence of PMPs in their food or feed crops could dry up lucrative 
markets, particularly in nations with markets hostile toward GM crops. This concern 
recently became a reality when Ventria’s proposal to grow rice that has been genetically 
modified to produce a pharmaceutical compound in Missouri prompted Anheuser-Busch 
and riceland Foods to threaten to boycott all rice produced in Missouri (Kasler, 005).
Stewardship and management issues may also pose a challenge to the developers of 
GM-forestry applications, particularly given the long lifetimes of plantation trees. While 
somewhat different, given the food application, there have already been two incidents over 
gene flow from GM papaya trees to conventional papaya trees in Hawaii and Thailand 
(Creamer, 00; Elias, 00; Mathes, 005). As the technology moves forward, there 
almost certainly will be issues associated with managing gene flow from GM trees in 
plantations to trees in unmanaged forests. 
Managing plants to prevent unintended gene flow is less likely to be a concern with 
GM plants intended for phytoremediation since such plants are intended to be used on 
contaminated sites, far from any food or feed crops. How these plants are disposed of, 
however, will need to be the subject of careful consideration so that further soil contami-
nation does not take place and to ensure these plants do not inadvertently move into the 
food or feed chain.
Management and stewardship issues are particularly troubling for university and 
other non-profit researchers who generally lack the experience of navigating regulatory 
requirements and managing long-term field trials under conditions of strict confinement. 
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Moreover, university researchers frequently lack the infrastructure and funding for such 
activities, an issue discussed in more detail below. 
Management and stewardship requirements have clearly emerged as a significant 
hurdle—in money, resources, and time—on the road to product commercialization or 
deployment. What has made it even more difficult, of course, for developers and inves-
tors trying to make judgments about development costs, is that there remain significant 
uncertainties about the standards to which developers are expected to adhere. Clearly, the 
development of gene-expression restriction technologies, like those described by roger 
Beachy elsewhere in this volume, would go a long way to reducing the costs of managing 
unwanted gene flow.
Regulatory	Requirements—Direct	Costs
The third major “speed bump” in the road to product commercialization is the regulatory 
review and approval process. regulations impose additional costs on the development 
of bioengineered plants compared to improved varieties created through conventional 
breeding, but it is difficult to estimate the cost with any great precision (Alston and 
Kalaitzandonakes, 005). Certainly much of the product-testing and development work 
required by regulators would be conducted by developers in any case, simply as a part 
of ensuring the quality, safety and performance of a new GM plant. As noted above, 
management and stewardship costs would, in many cases, be required by prudent busi-
ness practices even in the absence of regulation. But, plainly, the costs associated with 
additional testing, data production, data-package submission, and the time associated 
with regulatory review, are significant. Costs for some of the initial GM-crop approvals 
have been estimated at $5 million to $5 million (Alston, 00). Some analysts have 
estimated that half of all total development costs are associated with regulatory require-
ments (PIFB, 00a). However, these costs have not been well characterized and studies 
are ongoing to obtain some independent analysis of those estimates.
One of the factors affecting the costs of regulatory approval is the novelty of the trait or 
the novelty of the product in which the trait is being inserted. Not surprisingly, regulators 
tend to approach novel issues with greater caution, often demanding more studies and 
additional information to help answer their questions. As a result, first products through 
the regulatory system unquestionably bear a disproportionate amount of the regulatory 
burden. today, it is unlikely that approval of a commodity food crop with a genetic con-
struct already approved by the regulatory agencies would cost as much or take as long as 
the initial approval. On the other hand, a recent report by the Center for Science in the 
Public Interest noted that the time for regulatory approval of a new GM plant appears 
to be growing longer, not shorter, even though the plants being reviewed did not seem 
to present novel regulatory issues (Jaffe, 005, this volume). 
Costs	for	some	of	the	initial	GM-crop	approvals	have	been	
estimated	at	$5	million	to	$15	million.
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Once again, the regulatory approval hurdle places a disproportionate burden on 
university and other non-profit researchers who lack the experience with navigating the 
regulatory agencies and, perhaps more importantly, often lack the funding to carry out 
the required testing and to prepare the regulatory approval documents. Most non-profit 
researchers rely on government or foundation grants that typically support basic research, 
but not the kind of “regulatory science” needed to develop the data package to obtain 
product approvals (PIFB, 00a).  
Regulatory	Requirements—Indirect	Costs
The most visible cost of regulation is the direct cost of testing, data submission, and delay. 
Delaying the time in which the product can come to market imposes real costs, particularly 
for products that have time-limited intellectual property protection.
Beyond these direct costs is another, perhaps less obvious set of costs associated with 
regulatory uncertainty. In this case, the issue is not so much about what the regulations 
currently require, but uncertainty about what the regulations might require in the future. 
Without clarity from an agency about what a product approval requires, it is impossible 
for developers and potential investors to estimate the total costs of bringing a product to 
market. today, for example, a developer may have a fairly good sense of what it would 
cost to bring another Bt or herbicide-tolerance gene through the regulatory system. But 
the question of what it will cost to approve a different type of trait—such as a drought-
resistance gene—is much less certain. That kind of uncertainty discourages private-sector 
investment.
While some parts of the regulatory framework are relatively clear, others are not. As 
noted previously, agencies have not addressed the issue of adventitious presence except 
through permit requirements intended to prevent it from occurring. Even here, the rules 
continue to shift, as occurred in 003 when USDA increased setback requirements and 
other conditions on PMP permits, sharply limiting where PMP field trials could be 
conducted. The White House Office of Science and technology Policy has called on 
EPA, FDA and USDA to adopt rules to address adventitious presence resulting from 
field trials of GM crops intended for use as food or feed (OStP, 00), but there has 
been no similar call for guidance on plants not intended for use as food or feed—such as 
PMPs. While USDA has indicated that PMPs will always remain under APHIS permit, 
the Food and Drug Administration (FDA) could also exercise its authority over the drug-
manufacturing process to oversee the planting, growing, harvesting, and transporting of 
PMPs (FDA, 00).
New products inevitably raise novel issues for regulators. For example, it is not clear how 
plants modified through biotechnology for phytoremediation purposes will be regulated. 
While USDA’s rules with respect to transport and field testing would certainly appear 
to apply, EPA has asserted that it has the authority—not exercised to date—to regulate 
plants intended for commercial bioremediation under the toxic Substances Control Act 
as “new chemical substances” (EPA, 005).
Likewise, while USDA’s authority over GM trees is fairly clear, whether USDA will 
“deregulate” long-lived trees intended for plantations—or what information it would 
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require to make that decision—is much less clear. (EPA would presumably be in charge 
of approving pest-resistant trees under the pesticide laws.) Even more opaque is how 
USDA would make a decision to approve the release of a GM disease-resistant chestnut 
intended to grow and spread in unmanaged forests.
It’s worth noting here that the regulatory system for GM plants is a paragon of clarity 
compared to the regulatory system for transgenic animals, where we still lack any formal 
statement from the administration as to what agency is responsible for what decisions 
about transgenic animals. 
Finally, the ever-changing international regulatory environment poses an additional 
set of challenges for plant products that move out of the United States. In addition to 
specific laws adopted by countries with respect to GM foods and GM crops, the Cartagena 
Protocol on Biosafety continues to evolve and will certainly affect the inter-boundary 
transportation of any type of genetically modified organism, including plants and trees. 
How the Cartagena Protocol will continue to evolve and whether it will impose new legal 
or regulatory requirements remain a major source of uncertainty.
Marketplace	Acceptance
The final hurdle is, of course, the test of the marketplace. As with any new product, the 
question will be whether buyers are willing to pay a price for it that returns a profit to 
its developers.
Are there any unique marketplace challenges that face health and environmental ap-
plications of plant biotechnology? The history of the introduction of GM foods offers a 
cautionary tale. regardless of regulatory approvals, consumers in a number of countries 
remain suspicious about, and hostile to, GM crops and foods. In a market where consum-
ers have alternative choices, their rejection of GM foods has had an enormous impact on 
trade and has dramatically slowed the introduction of new varieties of GM foods. Farm-
ers, food manufacturers, grain processors and distributors and others have balked at the 
introduction of new GM varieties out of concern over negative consumer and marketplace 
reaction. GM potatoes, GM wheat, and GM sugar beets are all examples of products that 
made it through the regulatory process, but were rejected in the marketplace. 
There are a number of reasons to believe that consumer and market attitudes toward 
non-food products of plant biotechnology may be different.
First, there is some reason to believe that the opposition to biotechnology is tied to 
its use as food. While there are environmental and other concerns about GM plants in 
Europe, the strongest opposition is associated with GM food products, and the oppo-
sition is based in large part on fears about safety (Allum et	al., 003). In comparison, 
there has been little opposition to the non-food products of GM plants, such as cotton. 
For example, there has been little consumer opposition to blue jeans and few demands 
that they be labeled. So there is some reason to believe that the stigma attached to food 
biotechnology in some parts of the world may not automatically translate to other non-
food applications of plant biotechnology.
Second, since the public is the ultimate buyer and consumer of GM foods, its choices 
have enormous influence on the food-marketing chain. Farmers may be enthusiastic 
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buyers of GM seeds, but unless they can find markets for their crops, they will buy 
something else. Interestingly, consumers appear to be most concerned about foods that 
contain GM ingredients but there is far less concern about meat or milk from animals 
fed with GM grains.
In most of the non-food health and environmental applications of biotechnology, 
however, the public is not the buyer, and the products and services they ultimately receive 
are not “genetically modified.” For example, the buyers of lumber and pulp are simply 
businesses that, like farmers, are concerned primarily with cost and performance. The 
forestry products ultimately bought by consumers—paper, cardboard, houses—do not 
contain “GMOs.”
Similarly, the “product” bought and used by consumers from GM plants that produce 
PMPs is the drug or therapeutic protein itself—typically prescribed by a doctor and ap-
proved by the FDA. Again, the product will be long divorced from the process by which 
it was made. 
Third, at least some of the consumer opposition to GM food has been the result of a 
risk-benefit consideration where consumers see no benefit in the current generation of 
GM foods and elevated risk. Health and environmental plant-biotechnology applications, 
almost by definition, offer the prospects either for public benefits or direct consumer 
benefits. Using plants to produce lower-cost, potentially safer drugs has the strong sup-
port of a number of disease-research advocacy groups.
The fact is, consumers do make distinctions among applications of plant biotechnology 
(PIFB, 005). It should not be surprising, for instance, that in light of the above discus-
sion, the applications of plant biotechnology most strongly supported by Americans are 
those that would provide lower-cost pharmaceuticals or that would reduce world hunger 
(Figure ).
Figure . ratings of “very good” or “somewhat good” reasons, respectively,
to produce GM plants (PIFB, 005).
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Nevertheless, given the history of predictions about biotechnology, one must be humble 
when predicting the future. It frankly is too early to know whether the stigma against 
GM technology in some parts of the world will cling to these health and environmental 
applications. Mixed in with concerns about food safety are environmental concerns 
and embedded cultural, social, and economic issues that are often not clearly expressed. 
Even in the absence of a food-safety issue and direct consumer concerns, some of these 
other issues could still surface as opposition that could impact the market acceptability 
of these products.
In particular, the use of biotechnology in forestry will almost certainly be controversial, 
if for no other reason than, as with aquaculture and agriculture, there already are strong 
disagreements about the role of intensive forestry practices. to the extent that biotechnol-
ogy makes plantation forests more economically viable, it is likely that it will be opposed 
by those who are already critical of existing forestry practices. In addition, forests have a 
cultural significance that row crops do not. In a PIFB-sponsored conference in 00, a 
number of speakers referred to the emotional and moral value that people place on forests 
as natural places worthy of protection and respect. As a consequence, people are more likely 
to view the use of genetic modification technologies in forestry as unnatural, which could 
conceivably translate into opposition to forest products derived from GM trees along the 
lines of similar campaigns relating to “sustainable” forestry (PIFB, 00). 
On the other hand, potential environmental benefits from this technology may be ap-
pealing to some of the same segment of the public. For example, the ability to grow trees 
that require less energy to produce paper and pulp could be seen as an environmental 
benefit, not to mention the development of disease-resistant varieties of elm, chestnut, 
and dogwood. And the ability to create disease-resistant strains of key tree species could 
introduce the unique ability to preserve species that otherwise might become extinct. As 
noted, concerns about PMPs have little to do with the products, but rather with the poten-
tial that gene flow could move unwanted biological materials into food or feed crops. 
GM plants intended for use in environmental clean ups present a different set of 
marketing issues, since the primary buyer is the government or a clean up contractor 
working under government standards. As with any treatment technology, regulators 
choosing a particular remediation technology must find the product to be “protective of 
human health and environment, maintain protection over time, and minimize untreated 
waste” (0 CFr 300. 30). For example, if a treatment technology is being selected for 
use in the clean up of a Superfund site, the EPA remedial project manager is required to 
consider nine factors to evaluate alternatives and determine the remedy preference, with 
cost being merely one of the considerations (EPA, 990). 
The environmental-technology market is highly risk-adverse (OtA, 985). Government 
and their contractors do not want to take a chance in adopting a technology that does not 
work and risks making a problem worse. EPA has noted that clean up-project managers 
will need strong assurances—and a viable backup plan in the event of failure—before they 
are likely to select phytoremediation as an option (EPA, 005). Community support is 
an additional factor in remediation-technology choices. If there is concern about the use 
of GM plants, public opposition could constrain the use of this particular technology.  
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On the other hand, communities could embrace GM phytoremediation as a cost-effec-
tive, quick, and more “natural” process than employing chemical or thermal destruction 
treatment processes, or more desirable than typical dig-and-dump techniques. It simply 
is too early, particularly without experience using GM phytoremediation in real-world 
clean up tests, to know what the public will accept.
Conclusion
The hurdles to commercialization of health and environmental plant-biotechnology 
applications are significant. Much about them is uncertain. Few developers have the 
kind of financial security or “bet the company” attitude to risk being the first product to 
“test” the system. Unquestionably, some potentially valuable applications remain sitting 
on bench shelves in universities and companies around the country waiting for someone 
else to go first. 
Nevertheless, there are reasons for cautious optimism. The regulatory system is slowly 
responding to the need to evolve for new and different types of biotechnology products. 
Management and stewardship requirements are becoming more clear. And experience 
suggests that the market welcomes safe, innovative products that provide perceived benefits 
to buyers and to the public. The marketplace makes distinctions between products—even 
between products made with biotechnology. 
Not surprisingly, Pew Initiative polls tend to show that when consumers see a strong 
benefit for themselves, their families, or their community, they respond positively. As 
this technology moves forward, the bulk of the concern and opposition may prove to 
be rooted in food and the unwillingness of affluent consumers to take a small perceived 
risk in the absence of a clear benefit. The challenge then to the developers is to ensure 
that the potential benefits of this technology are clearly explained to the public while the 
government continues to ensure safety. If developers can do that, then there is indeed a 
way to “get there from here.”
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